TipRanks
Go Ultimate55% OFF

Schrodinger (SDGR) Revenue by Type

Revenue by Type

Separates revenue into product, services, subscription, license, milestone, and royalty streams so you can see which parts drive growth and margins. Heavy product/subscription revenue signals scalable, repeatable income, while concentration in milestone or one-time fees increases volatility and makes forecasts less reliable.

$0.00$20.00M$40.00M$60.00M$80.00MMar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

Software revenue is transitioning from lumpy, year‑end license peaks to steadier ratable hosted recognition — that supports ACV growth but depresses near‑term reported revenue and software gross margins as customers migrate. Meanwhile drug‑discovery receipts have surged thanks to accelerated collaboration recognition, giving a meaningful but inherently lumpy lift while contribution revenue has largely disappeared. Management’s maintained ACV guidance, hosted roadmap and upcoming AI product point to stronger recurring monetization long term, but expect near‑term revenue timing volatility and margin compression.

SDGR Revenue by Type

DateSoftware Products and ServicesDrug DiscoveryContributions
Jun 30, 2026$32.54M$22.99M$3.36M
Mar 31, 2026$35.56M$23.03M$0.00
Dec 31, 2025$69.28M$17.95M$0.00
Sep 30, 2025$40.86M$13.47M$0.00
Jun 30, 2025$40.54M$14.21M$0.00
Mar 31, 2025$48.82M$10.73M$0.00
Dec 31, 2024$79.70M$8.70M$0.00
Sep 30, 2024$31.88M$3.41M$0.00
Jun 30, 2024$35.40M$11.93M$0.00
Mar 31, 2024$33.41M$3.18M$0.00
Dec 31, 2023$68.70M$5.50M$0.00
Sep 30, 2023$28.90M$13.66M$0.00
Jun 30, 2023$29.35M$5.84M$0.00
Mar 31, 2023$32.21M$32.57M$0.00
Dec 31, 2022$47.80M$9.00M$0.00
Sep 30, 2022$24.67M$12.31M$0.00
Jun 30, 2022$30.01M$8.46M$0.00
Mar 31, 2022$33.08M$15.58M$0.00